Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson's disease.

Journal article

Bengoa-Vergniory N. et al, (2020), Nat Commun, 11

Understanding the pathophysiological role of early tau aggregates in Alzheimer's disease by their direct visualisation in situ

Conference paper

Velentza-Almpani E. et al, (2020), NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 46, 42 - 42

Selective vulnerability in α-synucleinopathies.

Journal article

Alegre-Abarrategui J. et al, (2019), Acta Neuropathol, 138, 681 - 704

Alpha-Synuclein Proximity Ligation Assay (AS-PLA) in Brain Sections to Probe for Alpha-Synuclein Oligomers.

Journal article

Roberts RF. et al, (2019), Methods Mol Biol, 1948, 69 - 76

Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease.

Journal article

Fields CR. et al, (2019), Front Mol Neurosci, 12

Alpha-synuclein oligomers: a new hope.

Journal article

Bengoa-Vergniory N. et al, (2017), Acta Neuropathol, 134, 819 - 838

Loss of MicroRNA-7 Regulation Leads to α-Synuclein Accumulation and Dopaminergic Neuronal Loss In Vivo.

Journal article

McMillan KJ. et al, (2017), Mol Ther, 25, 2404 - 2414

Colonic alpha-synuclein: A potential diagnostic biomarker in Parkinson's disease

Conference paper

Ruffmann C. et al, (2016), MOVEMENT DISORDERS, 31, S584 - S584

Load More